P Srikanth1, R F Chun2, M Hewison3, J S Adams2, R Bouillon4,5, D Vanderschueren4,5, N Lane6, P M Cawthon7, T Dam8, E Barrett-Connor9, L B Daniels9,10, J M Shikany11, M L Stefanick12, J A Cauley13, E S Orwoll14, C M Nielson1,15. 1. Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA. 2. Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. 3. Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, UK. 4. Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium. 5. Department of Endocrinology, University Hospital, Leuven, Belgium. 6. Division of Rheumatology, University of California Davis, Davis, CA, USA. 7. California Pacific Medical Center Research Institute, San Francisco, CA, USA. 8. Department of Medicine, Division of Geriatric Medicine and Aging, Columbia University, New York, NY, USA. 9. Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego, CA, USA. 10. Division of Cardiology, Department of Medicine, University of California, San Diego, CA, USA. 11. University of Alabama at Birmingham, Birmingham, AL, USA. 12. Stanford Prevention Research Center, School of Medicine, Stanford University, Stanford, CA, USA. 13. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 14. Bone and Mineral Unit, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, CR113, Portland, OR, 97239, USA. orwoll@ohsu.edu. 15. Bone and Mineral Unit, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, CR113, Portland, OR, 97239, USA.
Abstract
UNLABELLED: Vitamin D is hypothesized to suppress inflammation. We tested total and free vitamin D metabolites and their association with inflammatory markers. Interleukin-6 levels were lower with higher 25-hydroxyvitamin D. 1,25-dihydroxyvitamin D and free 25OHD associations mirrored those of 25OHD. However, associations for the two metabolites diverged for tumor necrosis factor alpha (TNF-α) soluble receptors. INTRODUCTION: Vitamin D is hypothesized to suppress inflammation, and circulating 25-hydroxyvitamin D (25OHD) and inflammatory markers are inversely correlated. However, total serum 25OHD may not be the best indicator of biologically active vitamin D. METHODS: We tested serum total 25OHD, total 1,25(OH)2D, vitamin D binding protein (DBP), and estimated free 25OHD and free 1,25(OH)2D associations with inflammatory markers serum interleukin-6 (IL-6), TNF-α and their soluble receptors, interleukin-10 (IL-10), and C-reactive protein (CRP) as continuous outcomes and the presence of ≥2 inflammatory markers in the highest quartile as a dichotomous outcome, in a random subcohort of 679 men in the Osteoporotic Fractures in Men (MrOS) study. RESULTS: IL-6 was lower in men with higher 25OHD (-0.23 μg/mL per standard deviation (SD) increase in 25OHD, 95 % confidence intervals (CI) -0.07 to -0.38 μg/mL) and with higher 1,25(OH)2D (-0.20 μg/mL, 95 % CI -0.0004 to -0.39 μg/mL); free D associations were slightly stronger. 25OHD and DBP, but not 1,25(OH)2D, were independently associated with IL-6. TNF-α soluble receptors were inversely associated with 1,25(OH)2D but positively associated with 25OHD, and each had independent effects. The strongest association with ≥2 inflammatory markers in the highest quartile was for free 1,25(OH)2D (odds ratios (OR) 0.70, 95 % CI 0.54 to 0.89 per SD increase in free 1,25(OH)2D). CONCLUSIONS: Associations of 1,25(OH)2D and free 25OHD with IL-6 mirrored those of 25OHD, suggesting that 1,25(OH)2D and free D do not improve upon 25OHD in population-based IL-6 studies. However, associations for the two metabolites diverged for TNF-α soluble receptor, warranting examination of both metabolites in studies of TNF-α and its antagonists.
UNLABELLED: Vitamin D is hypothesized to suppress inflammation. We tested total and free vitamin D metabolites and their association with inflammatory markers. Interleukin-6 levels were lower with higher 25-hydroxyvitamin D. 1,25-dihydroxyvitamin D and free 25OHD associations mirrored those of 25OHD. However, associations for the two metabolites diverged for tumor necrosis factor alpha (TNF-α) soluble receptors. INTRODUCTION:Vitamin D is hypothesized to suppress inflammation, and circulating 25-hydroxyvitamin D (25OHD) and inflammatory markers are inversely correlated. However, total serum 25OHD may not be the best indicator of biologically active vitamin D. METHODS: We tested serum total 25OHD, total 1,25(OH)2D, vitamin D binding protein (DBP), and estimated free 25OHD and free 1,25(OH)2D associations with inflammatory markers serum interleukin-6 (IL-6), TNF-α and their soluble receptors, interleukin-10 (IL-10), and C-reactive protein (CRP) as continuous outcomes and the presence of ≥2 inflammatory markers in the highest quartile as a dichotomous outcome, in a random subcohort of 679 men in the Osteoporotic Fractures in Men (MrOS) study. RESULTS:IL-6 was lower in men with higher 25OHD (-0.23 μg/mL per standard deviation (SD) increase in 25OHD, 95 % confidence intervals (CI) -0.07 to -0.38 μg/mL) and with higher 1,25(OH)2D (-0.20 μg/mL, 95 % CI -0.0004 to -0.39 μg/mL); free D associations were slightly stronger. 25OHD and DBP, but not 1,25(OH)2D, were independently associated with IL-6. TNF-α soluble receptors were inversely associated with 1,25(OH)2D but positively associated with 25OHD, and each had independent effects. The strongest association with ≥2 inflammatory markers in the highest quartile was for free 1,25(OH)2D (odds ratios (OR) 0.70, 95 % CI 0.54 to 0.89 per SD increase in free 1,25(OH)2D). CONCLUSIONS: Associations of 1,25(OH)2D and free 25OHD with IL-6 mirrored those of 25OHD, suggesting that 1,25(OH)2D and free D do not improve upon 25OHD in population-based IL-6 studies. However, associations for the two metabolites diverged for TNF-α soluble receptor, warranting examination of both metabolites in studies of TNF-α and its antagonists.
Entities:
Keywords:
Elderly; Free 1,25(OH)2D; Free 25OHD; Inflammation; Men; Total 1,25(OH)2D; Total 25OHD
Authors: Ravinder J Singh; Robert L Taylor; G Satyanarayana Reddy; Stefan K G Grebe Journal: J Clin Endocrinol Metab Date: 2006-05-23 Impact factor: 5.958
Authors: Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone Journal: Contemp Clin Trials Date: 2005-10 Impact factor: 2.226
Authors: Kamil E Barbour; Robert Boudreau; Michelle E Danielson; Ada O Youk; Jean Wactawski-Wende; Nancy C Greep; Andrea Z LaCroix; Rebecca D Jackson; Robert B Wallace; Douglas C Bauer; Matthew A Allison; Jane A Cauley Journal: J Bone Miner Res Date: 2012-05 Impact factor: 6.741
Authors: David Reid; Barry J Toole; Susan Knox; Dinesh Talwar; Johann Harten; Denis St J O'Reilly; Scott Blackwell; John Kinsella; Donald C McMillan; A Michael Wallace Journal: Am J Clin Nutr Date: 2011-03-16 Impact factor: 7.045
Authors: Terence M Doherty; Kamlesh Asotra; Lorraine A Fitzpatrick; Jian-Hua Qiao; Douglas J Wilkin; Robert C Detrano; Colin R Dunstan; Prediman K Shah; Tripathi B Rajavashisth Journal: Proc Natl Acad Sci U S A Date: 2003-09-19 Impact factor: 11.205
Authors: Brenda W J H Penninx; Stephen B Kritchevsky; Anne B Newman; Barbara J Nicklas; Eleanor M Simonsick; Susan Rubin; Michael Nevitt; Marjolein Visser; Tamara Harris; Marco Pahor Journal: J Am Geriatr Soc Date: 2004-07 Impact factor: 5.562
Authors: Martin Hewison; Fiona Burke; Katie N Evans; David A Lammas; David M Sansom; Philip Liu; Robert L Modlin; John S Adams Journal: J Steroid Biochem Mol Biol Date: 2007-03 Impact factor: 4.292
Authors: Yong Zhang; Donald Y M Leung; Brittany N Richers; Yusen Liu; Linda K Remigio; David W Riches; Elena Goleva Journal: J Immunol Date: 2012-02-01 Impact factor: 5.422
Authors: Janice B Schwartz; J Christopher Gallagher; Rolf Jorde; Vivian Berg; Jennifer Walsh; Richard Eastell; Amy L Evans; Simon Bowles; Kim E Naylor; Kerry S Jones; Inez Schoenmakers; Michael Holick; Eric Orwoll; Carrie Nielson; Martin Kaufmann; Glenville Jones; Roger Bouillon; Jennifer Lai; Davide Verotta; Daniel Bikle Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958
Authors: D P Larner; C Jenkinson; R F Chun; C S J Westgate; J S Adams; M Hewison Journal: J Steroid Biochem Mol Biol Date: 2019-01-30 Impact factor: 4.292
Authors: Marc Blondon; Mary Cushman; Nancy Jenny; Erin D Michos; Nicholas L Smith; Bryan Kestenbaum; Ian H de Boer Journal: J Clin Endocrinol Metab Date: 2016-03-29 Impact factor: 5.958